Laurus Labs [LAURUSLABS] vs Mankind Pharma [MANKIND] Detailed Stock Comparison
Laurus Labs
NSE
Loading...
Mankind Pharma
NSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Laurus Labs wins in 5 metrics, Mankind Pharma wins in 15 metrics, with 0 ties. Mankind Pharma appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Laurus Labs | Mankind Pharma | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 88.70 | 54.55 | Mankind Pharma |
| Price-to-Book Ratio | 10.11 | 7.31 | Mankind Pharma |
| Debt-to-Equity Ratio | 60.05 | 58.43 | Mankind Pharma |
| PEG Ratio | 35.87 | 41.13 | Laurus Labs |
| EV/EBITDA | 38.44 | 35.74 | Mankind Pharma |
| Profit Margin (TTM) | 8.58% | 14.66% | Mankind Pharma |
| Operating Margin (TTM) | 16.90% | 17.59% | Mankind Pharma |
| EBITDA Margin (TTM) | 16.90% | 17.59% | Mankind Pharma |
| Return on Equity | 7.79% | 13.67% | Mankind Pharma |
| Return on Assets (TTM) | 3.84% | 7.17% | Mankind Pharma |
| Free Cash Flow (TTM) | $-393.50M | $18.83B | Mankind Pharma |
| Dividend Yield | 0.18% | 0.04% | Laurus Labs |
| 1-Year Return | 92.79% | 15.49% | Laurus Labs |
| Price-to-Sales Ratio (TTM) | 7.63 | 8.11 | Laurus Labs |
| Enterprise Value | $478.42B | $1,109.27B | Mankind Pharma |
| EV/Revenue Ratio | 8.07 | 8.59 | Laurus Labs |
| Gross Profit Margin (TTM) | 59.39% | 70.49% | Mankind Pharma |
| Revenue per Share (TTM) | $110 | $317 | Mankind Pharma |
| Earnings per Share (Diluted) | $9.45 | $46.52 | Mankind Pharma |
| Beta (Stock Volatility) | 0.36 | 0.35 | Mankind Pharma |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Laurus Labs vs Mankind Pharma Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Laurus Labs | -1.96% | -3.24% | 5.60% | 40.07% | 31.21% | 33.49% |
| Mankind Pharma | -2.79% | -3.87% | 1.46% | 1.13% | -1.40% | -14.37% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Laurus Labs | 92.79% | 45.16% | 306.88% | 763.92% | 763.92% | 763.92% |
| Mankind Pharma | 15.49% | 76.92% | 76.92% | 76.92% | 76.92% | 76.92% |
Performance & Financial Health Analysis: Laurus Labs vs Mankind Pharma
| Metric | LAURUSLABS | MANKIND |
|---|---|---|
| Market Information | ||
| Market Cap | ₹452.51B | ₹1.05T |
| Market Cap Category | Large cap | Large cap |
| 10 Day Avg. Volume | 4,506,900 | 516,419 |
| 90 Day Avg. Volume | 3,124,373 | 789,842 |
| Last Close | ₹821.85 | ₹2,467.10 |
| 52 Week Range | ₹417.70 - ₹922.50 | ₹2,028.05 - ₹3,054.80 |
| % from 52W High | -10.91% | -19.24% |
| All-Time High | ₹922.50 (Jul 30, 2025) | ₹3,054.80 (Dec 23, 2024) |
| % from All-Time High | -10.91% | -19.24% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.31% | 0.23% |
| Quarterly Earnings Growth | 12.03% | -0.18% |
| Financial Health | ||
| Profit Margin (TTM) | 0.09% | 0.15% |
| Operating Margin (TTM) | 0.17% | 0.18% |
| Return on Equity (TTM) | 0.08% | 0.14% |
| Debt to Equity (MRQ) | 60.05 | 58.43 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | ₹82.94 | ₹347.39 |
| Cash per Share (MRQ) | ₹2.67 | ₹61.20 |
| Operating Cash Flow (TTM) | ₹4.13B | ₹26.50B |
| Levered Free Cash Flow (TTM) | ₹3.58B | ₹19.91B |
| Dividends | ||
| Last 12-Month Dividend Yield | 0.18% | 0.04% |
| Last 12-Month Dividend | ₹1.20 | ₹1.00 |
Valuation & Enterprise Metrics Analysis: Laurus Labs vs Mankind Pharma
| Metric | LAURUSLABS | MANKIND |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 88.70 | 54.55 |
| Forward P/E | 35.87 | 41.13 |
| PEG Ratio | 35.87 | 41.13 |
| Price to Sales (TTM) | 7.63 | 8.11 |
| Price to Book (MRQ) | 10.11 | 7.31 |
| Market Capitalization | ||
| Market Capitalization | ₹452.51B | ₹1.05T |
| Enterprise Value | ₹478.42B | ₹1.11T |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 8.07 | 8.59 |
| Enterprise to EBITDA | 38.44 | 35.74 |
| Risk & Other Metrics | ||
| Beta | 0.36 | 0.35 |
| Book Value per Share (MRQ) | ₹82.94 | ₹347.39 |
Financial Statements Comparison: Laurus Labs vs Mankind Pharma
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | LAURUSLABS | MANKIND |
|---|---|---|
| Revenue/Sales | ₹15.70B | ₹35.70B |
| Cost of Goods Sold | ₹6.37B | ₹10.54B |
| Gross Profit | ₹9.32B | ₹25.17B |
| Research & Development | N/A | N/A |
| Operating Income (EBIT) | ₹2.65B | ₹6.28B |
| EBITDA | ₹3.93B | ₹9.30B |
| Pre-Tax Income | ₹2.24B | ₹5.40B |
| Income Tax | ₹631.40M | ₹958.70M |
| Net Income (Profit) | ₹1.62B | ₹4.45B |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | LAURUSLABS | MANKIND |
|---|---|---|
| Cash & Equivalents | ₹995.40M | ₹4.07B |
| Total Current Assets | ₹43.32B | ₹69.88B |
| Total Current Liabilities | ₹35.40B | ₹56.64B |
| Long-Term Debt | ₹7.08B | ₹55.40B |
| Total Shareholders Equity | ₹46.03B | ₹145.68B |
| Retained Earnings | ₹36.26B | ₹119.07B |
| Property, Plant & Equipment | ₹1.89B | ₹29.08B |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | LAURUSLABS | MANKIND |
|---|---|---|
| Operating Cash Flow | N/A | ₹3.41B |
| Capital Expenditures | N/A | ₹-1.30B |
| Free Cash Flow | N/A | ₹3.51B |
| Debt Repayment | N/A | ₹-191.39M |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | LAURUSLABS | MANKIND |
|---|---|---|
| Shares Short | N/A | N/A |
| Short Ratio | N/A | N/A |
| Short % of Float | N/A | N/A |
| Average Daily Volume (10 Day) | 4,506,900 | 516,419 |
| Average Daily Volume (90 Day) | 3,124,373 | 789,842 |
| Shares Outstanding | 539.25M | 412.58M |
| Float Shares | 362.33M | 105.99M |
| % Held by Insiders | 0.32% | 0.74% |
| % Held by Institutions | 0.32% | 0.18% |
Dividend Analysis & Yield Comparison: Laurus Labs vs Mankind Pharma
| Metric | LAURUSLABS | MANKIND |
|---|---|---|
| Last 12-Month Dividend | ₹1.20 | ₹1.00 |
| Last 12-Month Dividend Yield | 0.18% | 0.04% |
| 3-Year Avg Annual Dividend | ₹1.33 | ₹0.33 |
| 3-Year Avg Dividend Yield | 0.16% | 0.04% |
| 3-Year Total Dividends | ₹4.00 | ₹1.00 |
| Ex-Dividend Date | May 09, 2025 | Aug 08, 2025 |